Investment Thesis
Cabaletta Bio is a pre-revenue, clinical-stage biopharmaceutical company burning $42.6M quarterly with no commercial product revenue. Despite a strong cash position of $116.6M and zero debt, the company has only ~2.7 years of runway at current burn rates, requiring successful clinical execution and capital raise within near term to survive.
Strengths
- Strong cash position of $116.6M provides 2.7+ years operational runway at current burn rate
- Zero debt and debt/equity ratio of 0.00x provides clean balance sheet with no solvency risk
- Healthy current and quick ratios of 2.95x indicates adequate short-term liquidity to fund operations
Risks
- Pre-revenue company with no commercialized products generating customer income
- Quarterly operating losses of $44.3M and cash burn of $42.6M are unsustainable without inflection event
- Limited runway of 2.7 years requires successful financing, partnership, or clinical milestone within near term or dilution risk escalates
- Development-stage biotech dependent entirely on pipeline success; clinical failure, regulatory delays, or financing challenges eliminate value
Key Metrics to Watch
- Quarterly cash burn rate and cash runway timeline (next financing inflection point)
- Clinical trial progress, data readouts, and regulatory pathway advancement
- Strategic partnerships, licensing deals, or revenue-generating catalysts that extend runway or establish commercial viability
Financial Metrics
Revenue
N/A
Net Income
-43.5M
EPS (Diluted)
$-0.39
Free Cash Flow
-42.6M
Total Assets
148.1M
Cash
116.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-42.1%
ROA
-29.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.95x
Quick Ratio
2.95x
Debt/Equity
0.00x
Debt/Assets
30.3%
Interest Coverage
-69.65x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T07:57:57.527039 |
Data as of: 2026-03-31 |
Powered by Claude AI